Oocyte Quality and in Vitro Fertilization Outcome in Triggering With Gnrh Agonist Versus Hcg Publisher



Bandarian F^{1, 2} ; Bandarian M³ Show Affiliations
Source: Gazzetta Medica Italiana Archivio per le Scienze Mediche Published:2023

Abstract

BACKGROUND: Currently two protocols including Human chorionic gonadotropin (hCG) and gonadotropin-releasing hormone (GnRH) agonist are used for ovulation triggering in assisted reproduction technology (ART) cycles. This study was designed to investigate the effect of GnRH agonist vs. hCG on oocyte quality and IVF (in vitro fertilization) outcome. METHODS: In this prospective study, 110 infertile women candidates for IVF, with antagonist cycle, were included. Eligible women at risk for ovarian hyperstimulation syndrome (OHSS), received GnRH agonist triggering and the rest of the women received hCG trigger. The primary outcomes were the number of retrieved oocytes and metaphase II oocytes, and the secondary outcome were the number of 2PN and chemical and clinical pregnancy rates. RESULTS: 110 infertile women participated in this study; 52 in GnRH agonist and 58 in the hCG group. Two groups were similar in BMI and duration of infertility (P>0.05). GnRH agonist group had higher AMH and AFC. The number of the retrieved oocyte, mature oocyte, G1 oocyte (high quality oocyte), and 2PN was higher in the GnRH agonist group (P value <0.01), but maturation rate, fertilization rate, number of embryo freeze, high-grade embryo, chemical, and clinical pregnancy rate were similar (P value>0.01) between the two groups. CONCLUSIONS: GnRH agonist trigger has some beneficial effect over hGC on oocyte quality and IVF outcome beyond the OHSS prevention, especially in patients who are candidates for freeze embryo transfer due to the destructive effect of this drug on fresh embryo transfer. © 2022 EDIZIONI MINERVA MEDICA.